Oncology How today’s biotechs are helping us Stand Up To Cancer In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.
News New radiopharma Actithera emerges with $75.5m in financing A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.
News FDA won't approve Summit, Akeso's ivonescimab The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.